Equities analysts expect CTI BioPharma Corp (NASDAQ:CTIC) to report sales of $10.30 million for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for CTI BioPharma’s earnings, with the highest sales estimate coming in at $10.50 million and the lowest estimate coming in at $10.10 million. CTI BioPharma reported sales of $750,000.00 in the same quarter last year, which would indicate a positive year over year growth rate of 1,273.3%. The company is expected to report its next earnings results on Wednesday, May 2nd.
On average, analysts expect that CTI BioPharma will report full year sales of $10.30 million for the current fiscal year, with estimates ranging from $10.56 million to $12.00 million. For the next fiscal year, analysts forecast that the company will post sales of $18.34 million per share, with estimates ranging from $14.69 million to $22.00 million. Zacks’ sales averages are a mean average based on a survey of research analysts that cover CTI BioPharma.
CTI BioPharma (NASDAQ:CTIC) last posted its quarterly earnings data on Wednesday, March 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.04). The firm had revenue of $0.46 million during the quarter, compared to analysts’ expectations of $1.00 million. CTI BioPharma had a negative net margin of 161.74% and a negative return on equity of 233.13%. During the same period in the previous year, the company earned ($0.70) earnings per share.
NASDAQ:CTIC remained flat at $$3.89 on Friday. 85,371 shares of the company’s stock were exchanged, compared to its average volume of 415,898. The company has a current ratio of 2.44, a quick ratio of 2.41 and a debt-to-equity ratio of 0.90. The stock has a market cap of $226.13, a PE ratio of -3.14 and a beta of 0.14. CTI BioPharma has a one year low of $2.45 and a one year high of $4.52.
In other CTI BioPharma news, insider Value Fund L. P. Biotechnology acquired 6,333,333 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The shares were purchased at an average price of $3.00 per share, for a total transaction of $18,999,999.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Bvf Partners L. P/Il acquired 5,634,108 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The shares were acquired at an average price of $3.00 per share, for a total transaction of $16,902,324.00. The disclosure for this purchase can be found here. Company insiders own 2.72% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC acquired a new stake in CTI BioPharma during the fourth quarter worth about $472,000. Renaissance Technologies LLC raised its stake in CTI BioPharma by 48.3% during the fourth quarter. Renaissance Technologies LLC now owns 609,849 shares of the biopharmaceutical company’s stock worth $1,634,000 after acquiring an additional 198,700 shares during the period. Stonepine Capital Management LLC raised its stake in CTI BioPharma by 84.8% during the fourth quarter. Stonepine Capital Management LLC now owns 1,834,838 shares of the biopharmaceutical company’s stock worth $4,917,000 after acquiring an additional 841,838 shares during the period. Kennedy Capital Management Inc. acquired a new stake in CTI BioPharma during the fourth quarter worth about $660,000. Finally, OxFORD Asset Management LLP acquired a new stake in CTI BioPharma during the third quarter worth about $164,000. Hedge funds and other institutional investors own 33.95% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first reported by Week Herald and is the property of of Week Herald. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://weekherald.com/2018/04/19/analysts-anticipate-cti-biopharma-corp-ctic-will-announce-quarterly-sales-of-10-30-million.html.
CTI BioPharma Company Profile
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.